BeStock  
Stocks › Biotechnology › DNTH

Dianthus Therapeutics DNTH

US equityMarket cap rank #2087Biotechnology
$84.55 −$0.28 (-0.33%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $84.08 -0.56%
Open$83.62
Prev close$84.83
Day range$82.53 – $85.67
Volume799.7K
Market cap$4.76B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership129.0%+2.10 pts vs. prior quarter
Institutions holding347+15 vs. prior quarter
Insider trades (recent)26 buys / 24 sellsNet buying
Short interest16.59% of floatDays to cover 10.1 · as of 30 Oct 2026
Short-sale volume share22.5%5-day average of daily volume

Short-sale volume as % of daily volume

5%18%31%44%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$8.44M (12 inflow days, 8 outflow days).

Net flow by order size, last 20 sessions

+$5.7MSuper+$2.7MBig+$2.7MMid+$1.1MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 45.0% of shares outstanding.

Largest holders

  • FMR15.19%
  • T. Rowe Price Group, Inc.11.78%
  • BlackRock7.80%
  • Wellington Management Group5.74%
  • Fairmount Funds Management LLC4.51%
  • State Street Global Advisors4.50%
  • Vanguard Capital Management, LLC4.31%
  • Avidity Partners Management, L.P.3.74%

By investor type

  • Mutual Fund85.15%
  • Hedge Fund29.53%
  • VC/PE Fund10.19%
  • Public Company1.36%
  • Private Company0.99%
  • Sovereign Wealth Fund0.75%
  • Insurance Company0.37%
  • Government Pension Fund0.36%

Reported short interest has risen from 15.05% to 16.59% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +974,346 2.7%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +451,597 1.3%
FMR Mutual Fund 2026/Q3 +352,866 15.2%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +268,505 4.3%
BlackRock Mutual Fund 2026/Q3 +265,782 7.8%
Fisher Investments Mutual Fund 2026/Q3 +249,510 0.5%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +214,995 0.8%
State Street Global Advisors Mutual Fund 2026/Q3 +177,018 4.5%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +165,318 2.5%
Franklin Resources Mutual Fund 2026/Q3 +138,405 2.0%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +228,901 11.8%
State Street Global Advisors Mutual Fund 2026/Q3 +958,527 4.2%
BlackRock Mutual Fund 2026/Q3 +948,119 7.4%
Wellington Management Group Mutual Fund 2026/Q3 +634,099 5.7%
Jennison Associates LLC Mutual Fund 2026/Q3 +536,627 1.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
11 Nov 2026 Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer Derivative Exercise and Sale -124,042 $91.59 –
8 Nov 2026 Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer Intent to Sell (Form 144) -124,042 $86.03 –
16 Sep 2026 Edward Carr Chief Accounting Officer Derivative Exercise and Sale -20,000 $104.39 –
31 Aug 2026 Simrat Randhawa Executive VP and Head of R&D Derivative Exercise and Sale -23,124 $106.74 4,000
18 Aug 2026 Simon Read Independent Director Derivative Exercise and Sale -2,778 $117.55 –
12 Aug 2026 Adam Veness Senior Vice President Derivative Exercise and Retained +15,000 $18.17 15,000
9 Aug 2026 Anne McGeorge Independent Director Derivative Exercise and Sale -7,750 $111.41 –
9 Aug 2026 Simon Read Independent Director Derivative Exercise and Sale -2,777 $111.77 –
9 Aug 2026 Adam Veness Senior Vice President Derivative Exercise and Sale -20,000 $111.18 –
6 Aug 2026 Marino Garcia Chief Executive Officer Derivative Exercise and Sale -166,000 $110.76 65,292
8 Jul 2026 Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer Derivative Exercise and Sale -31,249 $101.97 –
16 Jun 2026 Adam Veness Senior Vice President Derivative Exercise and Sale -30,000 $81.38 –
31 May 2026 Simrat Randhawa Executive VP and Head of R&D Derivative Exercise and Sale -26,530 $91.37 4,000
20 May 2026 Alison Lawton Independent Chairperson Other Derivative Acquisition +6,090 $89.63 6,090
20 May 2026 Sujay Kango Independent Director Other Derivative Acquisition +6,090 $89.63 6,090
20 May 2026 Anne McGeorge Independent Director Other Derivative Acquisition +6,090 $89.63 6,090
20 May 2026 Jonathan Violin Independent Director Other Derivative Acquisition +6,090 $89.63 6,090
20 May 2026 Steven Romano Independent Director Other Derivative Acquisition +6,090 $89.63 6,090
20 May 2026 Paula Soteropoulos Independent Director Other Derivative Acquisition +6,090 $89.63 6,090
20 May 2026 Simon Read Independent Director Other Derivative Acquisition +6,090 $89.63 6,090

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 9,276,833 16.6% 10.1
15 Oct 2026 8,986,958 16.1% 10.2
30 Sep 2026 9,140,581 16.3% 8.3
15 Sep 2026 8,829,663 15.8% 14.4
31 Aug 2026 8,429,902 15.1% 15.3
14 Aug 2026 8,418,356 15.1% 11.5

Discussion

No comments yet — be the first to weigh in on DNTH.

Sign in to join the discussion.

Scroll to Top